Ishiguro, H., Masuda, N., Sato, N., Higaki, K., Morimoto, T., Yanagita, Y., . . . Toi, M. (2020). A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat.

Ishiguro, Hiroshi, et al. "A Randomized Study Comparing Docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) Followed By TC, and TC Followed By FEC for Patients With Hormone Receptor-positive HER2-negative Primary Breast Cancer." Breast Cancer Res Treat 2020.

Ishiguro, Hiroshi, et al. "A Randomized Study Comparing Docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) Followed By TC, and TC Followed By FEC for Patients With Hormone Receptor-positive HER2-negative Primary Breast Cancer." Breast Cancer Res Treat 2020.